Akero Therapeutics: Q4 Earnings Insights
Akero Therapeutics (NASDAQ:AKRO) reported its Q4 earnings results on Friday, February 25, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Akero Highlights Presentation Of New Analysis Of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence Of Histological Improvement In EFX-treated NASH Patients After 16 Weeks Of Treatment
Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks
Histological improvements were evident
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours.
Akero Therapeutics Reports Received FDA Fast Track Designation For Efruxifermin For Treatment Of NASH
Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug
Morgan Stanley Downgrades Akero Therapeutics to Equal-Weight, Announces $27 Price Target
Morgan Stanley analyst Matthew Harrison downgrades Akero Therapeutics (NASDAQ:AKRO) from Overweight to Equal-Weight and announces $27 price target.
B of A Securities Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $40
B of A Securities initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and announces Price Target of $40.
HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Lowers Price Target to $64
HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and lowers the price target from $68 to $64.